Compare Charles River Laboratories Intl. Inc (CRL) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs GE Aerospace — how do they compare? Charles River Laboratories Intl. Inc trades at $227.54 (market cap $11.14B), while GE Aerospace trades at $355.01 (market cap $369.06B). The key difference: GE Aerospace is far larger — about 33.1× Charles River Laboratories Intl. Inc's market cap, and GE Aerospace pays a 0.53% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | GE | |
|---|---|---|
Market Cap | $11.14B | $369.06B |
Sector | Health | Industrials |
52-Week High | $233.60 | $378.68 |
52-Week Low | $145.57 | $259.00 |
Enterprise Value | $14.00B | $378.36B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GE trades at $353.42, down 1.63% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near support at $351. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $1.86 exceeding expectations, while revenue grew to $45.86 billion in 2025. Analyst sentiment is strongly positive with a consensus buy rating and $397 price target, driven by robust aerospace demand and recent defense contract wins.
The outlook remains favorable given strong order growth and strategic investments, but risks include high valuation multiples (P/E of 43.94) and debt levels. Upside is supported by earnings momentum and institutional confidence, though investors should monitor execution on backlog conversion and macroeconomic pressures on the aerospace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
